HK Stock Market Move | JUNSHI BIO (01877) rose more than 3% in early trading, with the addition of two new indications for Tyvyt and inclusion of Toripalimab in the national medical insurance directory.

JUNSHI BIO (01877) rose by over 3% in early trading, and as of the time of writing, it was up by 3.23% at HK$24.28, with a trading volume of HK$3.177 million. In terms of news, JUNSHI BIO announced recently that its products Tropilimab Injection (trade name: Tuo Yi) and Ongocteziximab Injection (trade name: Jun Shi Da) have successfully been included in the Category B range of the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue (2025)" ("National Medical Insurance Catalogue"). The new version of the National Medical Insurance Catalogue will be officially implemented starting from January 1, 2026. As of the disclosure date of this announcement, the company's four commercialized products Tuo Yi, Adalimumab Injection (trade name: Jun Mai Kang), Hydrobromide Deumidinib Tablet (trade name: Min De Wei), and Jun Shi Da have all been included in the National Medical Insurance Catalogue. Tuo Yi has all 12 indications for which it is approved for sale in mainland China included in the National Medical Insurance Catalogue, making it the only anti-PD-1 monoclonal antibody drug used for the treatment of renal cancer, triple-negative breast cancer, and melanoma on the list; Jun Shi Da is included for the first time, being the only domestically-produced PCSK9 targeting drug for statin-intolerant populations in the new version of the catalogue.